Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of NCR102 Injection for acute graft-versus-host disease
CTR20253620Phase 2Active
- Sponsor
- Zhongsheng Suyuan
- Start
- May 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of NCR102 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Zhongsheng Suyuan. Started May 2025; status: active.
02
Drugs
NCR102
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20253620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253620.